Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABMSCs for Ischemic Stroke
NCT06997939Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow derived mesenchymal stromal cells in ischemic stroke, sponsored by Affiliated Hospital of Nantong University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06997939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997939.